Characteristic | Baseline (n = 163) | Subpopulation at 24-month follow-upa (n = 89) |
---|---|---|
 | n (%) | n (%) |
Age at enrollment, years | 52.4 (6.5)b | 57.3 (5.7)b |
   40–49 | 59 (36) | 10 (11) |
   50–59 | 75 (46) | 43 (48) |
   60–69 | 29 (18) | 36 (40) |
Race | Â | Â |
   Caucasian | 150 (92) | 82 (92) |
   Asian | 13 (8) | 7 (8) |
Number of pregnancies | Â | Â |
lasting at least 6 months | Â | n/a |
   0 | 31 (19) |  |
   1 | 27 (17) |  |
   2 | 59 (36) |  |
   3+ | 45 (28) |  |
Weight change since age 18 (kg) | +15.8 (14.4)b | n/a |
Body fat (%) | n/a | 36.8 (5.5)b |
Tumor receptor status | Â | Â |
   ER+ tumor | 124 (76) | n/a |
   PR+ tumor | 128 (79) | n/a |
   ER+/PR+ tumor | 107 (66) | n/a |
   ER+/PR tumor | 17 (10) |  |
   ER /PR+ tumor | 21 (13) |  |
   ER /PR tumor | 18 (11) |  |
Stage of disease | Â | Â |
   0, in situ | 51 (31) | n/a |
   I | 83 (51) |  |
   II | 29 (18) |  |
Subject genotypes | Â | Â |
   UGT1A1 genotypes (TA)6/(TA)7 |  |  |
   (TA)6/(TA)6 | 80 (49) | 49 (55) |
   (TA)6/(TA)7 | 72 (44) | 36 (40) |
   (TA)7/(TA)7 | 11 (7) | 4 (5) |
   (TA)7 allele frequency | 0.29 | 0.25 |
UGT2B4 genotypes (Asp458Glu) | Â | Â |
   Asp/Asp | 104 (64) | 53 (60) |
   Asp/Glu | 46 (28) | 29 (33) |
   Glu/Glu | 13 (8) | 7 (8) |
   Glu allele frequency | 0.22 | 0.24 |
UGT2B7 genotypes (His268Tyr) | Â | Â |
   His/His | 41 (25) | 24 (27) |
   His/Tyr | 73 (45) | 48 (54) |
   Tyr/Tyr | 49 (30) | 17 (19) |
   Tyr allele frequency | 0.52 | 0.46 |
UGT2B15 genotypes (Asp85Tyr) | Â | Â |
   Asp/Asp | 32 (20) | 19 (21) |
   Asp/Tyr | 83 (51) | 47 (53) |
   Tyr/Tyr | 48 (29) | 23 (26) |
   Tyr allele frequency | 0.55 | 0.52 |
SULT1A1 genotypes (Arg213His) | Â | Â |
   Arg/Arg | 71 (43) | 39 (44) |
   Arg/His | 68 (42) | 38 (43) |
   His/His | 24 (15) | 12 (13) |
   His allele frequency | 0.36 | 0.35 |